Turn Therapeutics (TTRX) CEO receives 160,000 stock options at $3.43 strike

Rhea-AI Filing Summary

Turn Therapeutics Inc. reported that Chief Executive Officer and director Burnam Bradley Evan received an employee stock option grant covering 160,000 shares of common stock at an exercise price of $3.43 per share. The option was granted as compensation at no purchase price on the grant date.

According to the vesting terms, 25% of the option will vest on the first anniversary of the grant date, with the remaining 75% vesting in equal installments over the following 36 months, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Burnam Bradley Evan, BEB Holdings, LLC

Role Chief Executive Officer | 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Employee stock option (right to buy)	160,000	$0.00	--

Holdings After Transaction: Employee stock option (right to buy) — 160,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 160,000 options Exercise price: $3.43 per share Transaction price: $0.00 per option +2 more

5 metrics

Options granted 160,000 options Employee stock option grant to CEO for common stock

Exercise price $3.43 per share Exercise price for the 160,000 employee stock options

Transaction price $0.00 per option Grant awarded at no cost on the grant date

Initial vesting portion 25% of options Vests on first anniversary of the grant date

Remaining vesting period 36 months Remaining 75% vests ratably over following 36 months

Key Terms

Employee stock option, exercise price, vesting, Omnibus Incentive Plan, +1 more

5 terms

Employee stock option financial

"Employee stock option (right to buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

exercise price financial

"conversion or exercise price of 3.4300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option will vest as follows: 25% will vest on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Omnibus Incentive Plan financial

"Issuer's 2025 Omnibus Incentive Plan"

An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.

grant, award, or other acquisition financial

"transaction code description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burnam Bradley Evan

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CALIFORNIA 91362

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$3.43	04/01/2026		A		160,000		(1)	(1)	Common Stock	160,000	$0	160,000	D

1. Name and Address of Reporting Person^*

Burnam Bradley Evan

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CALIFORNIA 91362

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

1. Name and Address of Reporting Person^*

BEB Holdings, LLC

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CALIFORNIA 91362

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The option will vest as follows: 25% will vest on the first anniversary of the grant date, with the remaining 75% vesting ratably over the following 36 months, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

	/s/ Bradley Burnam	04/03/2026
	/s/ Bradley Burnam, sole member of BEB Holdings, LLC	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Turn Therapeutics (TTRX) disclose for its CEO?

Turn Therapeutics disclosed that CEO Burnam Bradley Evan received an employee stock option grant for 160,000 shares. The options are compensation-based, not an open-market purchase, and give him the right to buy common stock at a fixed exercise price of $3.43 per share.

What are the key terms of the 160,000 stock options granted at Turn Therapeutics (TTRX)?

The grant covers 160,000 employee stock options with an exercise price of $3.43 per share. The options were awarded at no cost on the grant date and are tied to common stock, providing potential future ownership if exercised after vesting conditions are satisfied.

How do the CEO’s new Turn Therapeutics (TTRX) options vest over time?

The option vests 25% on the first anniversary of the grant date, with the remaining 75% vesting ratably over the next 36 months. Vesting requires continued employment and compliance with the terms of the company’s 2025 Omnibus Incentive Plan.

Is the Turn Therapeutics (TTRX) CEO’s option grant an open-market buy or compensation award?

The CEO’s transaction is a compensation-related award, not an open-market buy. The Form 4 labels it as a grant or award acquisition, with a transaction price of $0.00 per option and an exercise price of $3.43 for future share purchases.

How many Turn Therapeutics (TTRX) options does the CEO hold after this grant?

After this transaction, the CEO is reported as holding 160,000 employee stock options related to common stock. These options are subject to vesting over time and give him the right, but not the obligation, to purchase shares at $3.43 per share.